Prevention of Anti-BRAF-Induced Phototoxicity: not Just a Question of Photoprotector
Volume 3 - Issue 5
M Cormerais1, A Boisrobert2, H Dutartre2, A Khammari2 and B Dreno2*
-
Author Information
Open or Close
- 1Service de Dermatologie, CHU Pontchaillou, France
- 2Service de Dermatologie, CHU de Nantes, France
*Corresponding author:
B Dreno, Service de Dermatologie, CHU de Nantes, Place Alexis Ricordeau 44093 Nantes, France
Received:July 09, 2019; Published:July 17, 2019;
DOI: 10.32474/RRHOAJ.2019.03.000171
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Targeted therapies changed the prognosis of metastatic melanoma. Flaherty & al. and the BRIM-II study found a response rate between 53-81% and a median progression-free survival of about seven months [1,2]. The BRIM-III study reported a median survival of 13.6 months and a 6-month survival rate of 84% with Vemurafenib versus 9.7 months and 64% with dacarbazine [3]. The UVA-phototoxicity induced by Vemurafenib through a decrease in minimal erythema dose
Letter to Editor|
Acknowledgment|
References|